Amneal (AMRX) Q2 2026 earnings review
Broad-Based Growth and Guidance Raise Offset by AvKARE Weakness
Amneal delivered a robust Q2 2026 with revenue up 10% YoY to $796 million and GAAP net income surging 157% to $58 million. The top-line beat was driven by accelerating momentum in the Specialty and Affordable Medicines segments, which grew 17% and 13%, respectively, powered by key brands like CREXONT and a wave of complex generic launches. This performance gave management the confidence to raise full-year guidance across revenue, adjusted EBITDA, and EPS for the second time this year. While the AvKARE distribution segment contracted and SG&A expenses rose faster than revenue, the company's aggressive debt repricing and pending Kashiv Biosciences acquisition highlight a clear, vertically integrated growth strategy.
🐂 Bull Case
The pivot toward high-value, complex products is paying off. Specialty revenue jumped 17% and Affordable Medicines grew 13%, proving the commercial traction of assets like CREXONT, BREKIYA, and new complex generic launches.
A July debt repricing reduces the interest rate on a $2.084B term loan by 50 basis points, generating $12 million in annual cash savings. This, combined with top-line operating leverage, fueled a 20% YoY increase in Adjusted EPS.
🐻 Bear Case
AvKARE revenue declined 4% YoY due to weakness in the low-margin distribution channel. While partially offset by the government channel, the segment is a noticeable drag on overall consolidated growth.
SG&A expenses jumped nearly 20% YoY to $148.7 million. If revenue growth decelerates, this elevated cost structure could compress the operating margin.
⚖️ Verdict: 🟢
Bullish. The 10% top-line growth is high-quality, driven by the most profitable segments (Specialty and Affordable Medicines). The guidance raise and strategic debt reduction overshadow the targeted wind-down of lower-margin distribution revenue in AvKARE.
Key Themes
Kashiv Biosciences Acquisition
Amneal is formally pivoting to become vertically integrated in the biosimilars market via its pending Kashiv Biosciences transaction. Management highlighted this as an 'important new, durable growth vertical.' Securing $350 million in new Term Loan B financing to fund the acquisition indicates a major capital allocation shift toward owning the manufacturing and development of large-molecule therapies, rather than just commercializing them.
Specialty Brands Outperforming
Accelerating. The Specialty segment delivered an impressive 17% YoY revenue increase to $149 million. This was explicitly driven by key branded neurology and endocrinology products, specifically CREXONT (Parkinson's), the BREKIYA autoinjector (migraine), and UNITHROID. Non-GAAP gross margins in this segment remained incredibly healthy at 80.3%.
Affordable Medicines Pipeline Traction
Accelerating. Affordable Medicines segment revenue grew 13% YoY to $490 million. The growth is directly tied to the success of the complex generic portfolio, particularly women's health products and recent new product launches. The segment's Non-GAAP gross margin expanded slightly to 45.3% from 44.3% a year ago, reflecting a favorable mix shift away from commoditized oral solids.
Debt Repricing and Interest Savings
Stable. In July 2026, Amneal repriced its $2.084B Term Loan B, dropping the interest rate from SOFR + 300 bps to SOFR + 250 bps. This proactive financial engineering will generate approximately $12 million in annual cash interest savings, accelerating the company's path toward its target net leverage ratio of below 3.0x by 2028.
AvKARE Segment Decelerating
Decelerating/Reversing. AvKARE was the sole laggard, with net revenue decreasing 4% YoY to $157 million. Management cited a decline in the low-margin distribution channel, which was only partially offset by growth in the government channel. While exiting low-margin business aids profitability, it creates a persistent top-line headwind.
SG&A Expense Growing Faster Than Sales
Decelerating operating leverage. Selling, general, and administrative expenses increased from $124.3 million in Q2 2025 to $148.7 million in Q2 2026—a jump of nearly 20%, which outpaced the 10% consolidated revenue growth. While gross profit dollars expanded sufficiently to absorb this, the rising commercial cost base (likely tied to CREXONT and BREKIYA launches) requires careful monitoring.
Elevated Capital Expenditures Outlook
Management significantly raised the full-year 2026 capital expenditures guidance from ~$110 million to ~$150 million. While this reflects deposits for future property, plant, and equipment (likely to support the biosimilars pivot and internal manufacturing), it represents a notable drag on near-term free cash flow generation.
Other KPIs
Accelerating. Up 12% YoY from $184 million in Q2 2025. The growth was driven entirely by higher revenue volumes and a 250 bps expansion in GAAP gross margin (to 42.0%), overcoming the $24 million YoY increase in SG&A expenses.
Accelerating. Improved from 39.5% in the prior year period. Adjusted gross margin hit 46.2%, driven by the outsized 17% growth in the high-margin Specialty segment (80.3% adj. margin) and improved product mix in Affordable Medicines.
Stable. Net leverage increased slightly from 3.5x at the end of 2025 to 3.6x. Total gross debt sits at $2.78 billion against $127.6 million in cash and cash equivalents. The impending $350 million additional term loan for the Kashiv acquisition will push this ratio higher in the near term.
Guidance
Accelerating. Raised from the prior range of $3.05 - $3.15 billion. The midpoint ($3.15 billion) implies roughly 4.3% YoY growth compared to FY25 ($3.018 billion). The strong 10% Q2 beat gives management confidence in a stronger second half.
Accelerating. Raised from $740 - $770 million. The midpoint ($765 million) suggests an 11% YoY growth rate over FY25's $688 million, indicating that gross margin expansion and revenue scale are expected to continually outpace operating expenses.
Accelerating. Raised from $0.95 - $1.05. The midpoint of $1.01 represents an impressive 21% implied YoY growth compared to the $0.83 delivered in FY25, heavily assisted by the 50 bps interest rate reduction on the term loan.
Stable. Unchanged from prior guidance. Excluding discrete items (like opioid settlements and Kashiv integration costs), the core operating cash flow is projected between $375 million and $425 million.
Key Questions
AvKARE Strategic Review
With AvKARE revenues declining 4% as the company deliberately steps away from the low-margin distribution channel, what is the ultimate revenue floor for this segment, and is there any consideration to divest it entirely to focus capital on the higher-margin Specialty and Biosimilar verticals?
Kashiv Integration and Margin Drag
Regarding the pending Kashiv Biosciences acquisition, what is the expected near-term drag on consolidated Adjusted EBITDA margins and free cash flow as you invest in standing up the vertical integration infrastructure?
SG&A Run-Rate
SG&A grew 20% year-over-year in Q2. Should investors view the $148 million level as the new quarterly baseline required to support the CREXONT and BREKIYA launches, or are there one-time commercial investments embedded in this quarter?
CapEx Surge Allocation
Capital expenditures guidance was raised significantly from $110 million to $150 million. Can you break down how much of this $40 million increase is tied directly to domestic manufacturing build-outs versus deposits for future M&A or technology transfers?